Industry

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

– DCC-3116 Was Well-tolerated with No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events Observed – – Pharmacokinetic and Pharmacodynamic Data Across all Doses Levels Demonstrated Exposure and ULK 1/2 Inhibition Associated with Anti-cancer Efficacy in Preclinical Studies – – Selection of Starting Dose and Initiation of Combination Dose Escalation Cohorts with MEK and KRASG12C … [Read more…]

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

– In an oral presentation at ESMO 2022, data from the GDFATHER-1 trial showed that treatment with visugromab and the anti-PD-1 inhibitor nivolumab resulted in excellent tolerability and significant anti-tumor activity. All patients in the study were heavily pre-treated, last-line, advanced-stage solid tumor patients, who were relapsed on or refractory to prior anti-PD-1/PD-L1 treatment – … [Read more…]

Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctional Program, BCA101, at the European Society for Medical Oncology (ESMO) Congress 2022

– Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck – Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring Principal Investigator Glenn J. Hanna, M.D. CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to … [Read more…]

Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022

BOSTON–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC). The data show that poziotinib is highly active in G778 mutations in both treatment … [Read more…]

Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer

– Poster presentation at the 2022 Annual Meeting of the European Society of Medical Oncology (ESMO), Paris, France PALO ALTO, Calif.–(BUSINESS WIRE)–#innovation–Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled “Serum-based colorectal cancer detection using orphan noncoding RNAs” at the 2022 European … [Read more…]

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress

35 Percent of Patients Treated With CTP-543 12 mg Twice-Daily Achieved At Least 90 Percent Scalp Hair Coverage (SALT Score ≤ 10) After 24 Weeks of Treatment Newly-Reported Results Show Significant Improvement in Eyebrow and Eyelash Regrowth in Patients Treated With Both Doses of CTP-543 MILAN–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the … [Read more…]

DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer

Extended follow-up data from phase 1/2 trial of DS-7300 in patients with metastatic lung, prostate or esophageal cancer to be featured in Proffered Paper session at ESMO TOKYO, BASKING RIDGE, N.J. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and Sarah Cannon Research Institute (SCRI) announced that extended follow-up data from a phase 1/2 trial of … [Read more…]

Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

— WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function — — WU-NK-101 demonstrated robust anti-tumor activity, tumor trafficking, and penetration further augmented by monoclonal antibodies (mAbs) — — Data support the clinical development of WU-NK-101 for solid tumor indications — ST. LOUIS & … [Read more…]

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

– Both single-agent XL092 and XL092 in combination with atezolizumab demonstrated encouraging efficacy and safety in a heavily pretreated patient population – – XL092 demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile – – Based on … [Read more…]

Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis New analysis to be presented at the 2022 European Academy of Dermatology and Venereology Congress as part of 26 company-sponsored scientific presentations, demonstrating … [Read more…]